Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
- 1
- 2
Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Emerging Markets data
Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Methicillin-Resistant Staphyloccocus Aureus Infections (MRSA) | Current Treatment | Physician Insights | US | 2017
The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial…
Methicillin-Resistant Staphyloccocus Aureus Infections (MRSA) | Outpatient Parenteral Antibiotic Therapy (OPAT) | Current Treatment | Physician Insights | US | 2017
Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…
Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Asia Pacific Data
Methicillin-Resistant Staphylococcus aureus Epidemiology AbstractDRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient…
Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Middle East & Africa Data
Methicillin-Resistant Staphylococcus aureus EpidemiologyDRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient populations…
Methicillin-Resistant Staphylococcus Aureus Infections (MRSA) | Disease Landscape and Forecast | G7 | 2016
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…
Methicillin-Resistant Staphylococcus Aureus Infections (MRSA) | Current Treatment | US | 2016
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen in both the hospital and outpatient treatment settings. The recent FDA approvals of tedizolid (…
- 1
- 2
